Greater than 25% of all cancers have oncogene amplifications
More than 5 million newly diagnosed cancers each year around the world harbor oncogene amplifications. Unfortunately, there are no effective treatment options for the vast majority of these patients, resulting in poor prognosis and survival.
Despite substantial advances in the development of therapies for patients with cancers driven by oncogene mutations or fusions, the current generation of targeted therapies and immunotherapies has proven largely ineffective in patients with cancers driven by oncogene amplification.
Why We’re HereecDNA are a therapeutically actionable, unique vulnerability of cancer cells
ecDNA are rarely seen in healthy cells but are found in the cancer cells of over 17% of patients with solid tumor. Boundless Bio’s comprehensive approach to understanding the utilization of ecDNA by cancer allows us to identify and therapeutically exploit unique vulnerabilities of ecDNA in cancer cells.
What We Do
Why Boundless Bio?
Boundless Bio is the first company dedicated to treating oncogene amplified cancers and is the leader in the field of ecDNA, driving the discovery and development of a novel therapeutic approach to targeting oncogene amplified cancers.
With boundless innovation and boundless energy, our team of professional drug hunters is committed to developing powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
Who We Are